RecruitingNot ApplicableNCT05750901
Evaluation of Fractional Ablative Laser Treatment for Skin Conditions
Pilot Evaluation of Fractional Ablative Laser Treatment for Skin Laxity and Tightening
Sponsor
Sciton
Enrollment
1,000 participants
Start Date
Nov 1, 2022
Study Type
INTERVENTIONAL
Conditions
Summary
Evaluate the safety and efficacy of the fractional ablative laser for treatment of skin laxity and tightening
Eligibility
Min Age: 18 YearsMax Age: 85 Years
Inclusion Criteria7
- Male or female subjects aged 18-85 years
- Fitzpatrick skin type I-VI
- Has visible skin laxity in the treatment region or has a scar
- Post-menopausal or surgically sterilized, or using a medically acceptable form of birth control at least 3 months prior to enrollment and during the entire course of the study, and no plans to become pregnant for the duration of the study (Applicable to female subjects only)
- Willing to have digital imaging and measurements taken of the treatment area and agree to use for presentation, educational or marketing purposes
- Subject must be able to read, understand and sign Informed Consent Form in English
- Must be willing to adhere to the treatment and follow-up schedule and post-treatment care instructions
Exclusion Criteria15
- Participation in a clinical trial of another device or drug within 6 months prior to enrollment or during the study.
- Any type of prior cosmetic treatment to the target area at physicians' discretion
- History of malignant tumors in the target area.
- Skin abnormalities in the target area, e.g., cuts, scrapes, wounds, large moles.
- Pregnant and/or breastfeeding (Applicable to females only)
- Having an infection, dermatitis or a rash in the treatment area.
- Significant concurrent illness, such as diabetes mellitus, cardiovascular disease, e.g., uncontrolled hypertension or pertinent neurological disorders.
- Suffering from coagulation disorders or taking prescription anticoagulation medications.
- History of keloid scarring, hypertrophic scarring or of abnormal wound healing.
- History of immunosuppression/immune deficiency disorders or currently using immunosuppressive medications.
- History of vitiligo, eczema, or psoriasis.
- History of disease stimulated by heat, such as recurrent herpes simplex and/or herpes zoster (shingles) in the treatment area, unless treatment is conducted following a prophylactic regimen.
- History of radiation to the treatment area or undergoing systemic chemotherapy for the treatment of cancer.
- Current smoker or history of smoking within 6 months of study participation.
- As per the Investigator's discretion, any physical or mental condition which might make it unsafe for the subject to participate in this study
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DEVICEFractional ablative laser
Fractional ablative laser used for treatment for skin laxity and tightening
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05750901
Related Trials
A Study to Characterize Human Skin Changes From Biostimulator Treatments Via Non-invasive Imaging
NCT073990281 location
Ellacor® Micro-Coring Technology® in Fitzpatrick Skin Types I-VI, Including Patients Receiving Glucagon-Like Peptide-1 Receptor Agonists
NCT072248801 location
An Evaluation of the Erchonia Laser As a Non-Invasive Treatment to Improve the Appearance of Skin Laxity
NCT069416101 location
Effects of QUANTUM Probe for Skin Rejuvenation and Subdermal Retraction in Patients Undergoing High-Definition Liposculpture
NCT069589781 location
Safety and Efficacy Evaluation of High Intensity Focused Ultrasound Device in Eyebrow Lifting
NCT067245103 locations